RxDoctor Payments Data

James Pollard, MD

Cardiovascular Disease · Jackson, MSNPI 1174786651

Payments from drug & device makers

$952in general payments, 2019–2025

Across 44 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$218
  • Pfizer$216
  • Boehringer Ingelheim$131
  • Heartflow, Inc.$121
  • BTG International Inc.$101
  • Gilead$77
  • plus $88 from 6 others

What the payments were for

  • Food & beverage$93899%
  • Education$141%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$952 in reported general payments places this provider in the 20th percentile of 144 cardiovascular disease providers in Mississippi.

See all cardiovascular disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$104,634
Medicare patients
618
Services billed
2,081

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan57$54,701
EliquisApixaban65$52,470
BrilintaTicagrelor37$25,341
FarxigaDapagliflozin Propanediol11$16,343
JardianceEmpagliflozin12$14,330
Metoprolol Succinate132$1,927
Warfarin Sodium183$1,844
Hydralazine Hcl57$757
Midodrine Hcl12$684
Carvedilol96$650
Atorvastatin Calcium81$634
Losartan Potassium51$512
ClopidogrelClopidogrel Bisulfate36$374
Spironolactone43$340
Amlodipine Besylate42$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$218$54,70157 claims
PfizerEliquis$216$52,47065 claims
AstraZenecaBrilinta, Farxiga$14$41,68448 claims
Boehringer IngelheimJardiance$131$14,33012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 144 cardiovascular disease providers in Mississippi.

Other cardiovascular disease in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →